Trial Profile
A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to moderate facial seborrheic dermatitis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Omiganan (Primary) ; Ketoconazole
- Indications Seborrhoeic dermatitis
- Focus Therapeutic Use
- Sponsors Cutanea Life Sciences; Maruho
- 29 Apr 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 29 Apr 2019 Planned primary completion date changed from 1 May 2019 to 1 Dec 2019.
- 09 Nov 2018 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.